



SHEET OF 1

Form PTO 1449
(Modified)DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY DOCKET NO.
216008US0PCTSERIAL NO.
09/926,679

LIST OF REFERENCES CITED BY APPLICANT

APPLICANT
Fumiaki IKEDA, et al.FILING DATE
November 30, 2001GROUP
614

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB CLASS | FILING DATE IF APPROPRIATE |
|---------------------|----|--------------------|----------|-------------------|-------|--------------|-------------------------------|
| AM | AA | 5,030,619 | 07/09/91 | Richard F. HECTOR | 514 | 8 | |
| | AB | | | | | | |
| | AC | | | | | | |
| | AD | | | | | | |
| | AE | | | | | | |
| | AF | | | | | | |
| | AG | | | | | | |
| | AH | | | | | | |
| | AI | | | | | | |
| | AJ | | | | | | |
| | AK | | | | | | |
| | AL | | | | | | |
| | AM | | | | | | |
| | AN | | | | | | |

FOREIGN PATENT DOCUMENTS

| | | DOCUMENT NUMBER | DATE | COUNTRY | TRANSLATION YES | NO |
|----|----|--------------------|----------|---------|--------------------|----|
| AM | AO | WO 98/10782 | 03/19/98 | WIPO | | |
| AM | AP | WO 96/11210 | 04/18/96 | WIPO | | |
| | AQ | | | | | |
| | AR | | | | | |
| | AS | | | | | |
| | AT | | | | | |
| | AU | | | | | |
| | AV | | | | | |

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

| | | |
|----|----|--|
| AM | AW | S. P. FRANZOT, et al., Antimicrobial Agents and Chemotherapy, vol. 41, no. 2, pages 331-336, "PNEUMOCANDIN L-743,872 ENHANCES THE ACTIVITIES OF AMPHOTERICIN B AND FLUCONAZOLE AGAINST CRYPTOCOCCUS NEOFORMANS IN VITRO", February 1, 1997 |
| AM | AX | K. BARTIZAL, et al., Antimicrobial Agents and Chemotherapy, vol. 39, no. 5, pages 1070-1076, "IN VITRO EVALUATION OF THE PNEUMOCANDIN ANTIFUNGAL AGENT L-733560, A NEW WATER-SOLUBLE HYBRID OF L-705589 AND L-731373", May 1, 1995 |
| | AY | |
| | AZ | |

Examiner

Abdel A. Mohamed

Date Considered

11/7/03

*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.